Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NACA pseudogene 10 (NACAP10), also known as nascent polypeptide-associated complex alpha subunit 2 pseudogene, is annotated as a pseudogene in the human genome, mapped to chromosome 8 (chr8:67569416-67570078, hg38)[2][3]. Pseudogenes are genomic sequences related to protein-coding genes but do not encode functional proteins due to disabling mutations or lack of necessary regulatory elements[6]. NACAP10 is annotated in major genomic resources (e.g., NCBI Gene: 100132812, Ensembl: ENSG00000254253)[2][3], and is derived from or related to the parental gene NACA (nascent polypeptide-associated complex subunit alpha)[4]. There is no evidence for translated protein, disease associations, or utility as a therapeutic target, biomarker, or drug-interacting molecule. While some pseudogenes have been shown to regulate gene expression through non-coding RNA mechanisms in other gene families (e.g., through microRNA sponging or competitive endogenous RNA activity)[6], there is no such documented activity for NACAP10. Thus, NACAP10 is best classified as a noncoding genomic element with no known protein product or direct role in human health or disease[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NACA pseudogene 10 (NACAP10).